Boston Scientific Corporation announced on October 17, 2025 that it had entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company that develops the Nalu Neurostimulation System for chronic peripheral nerve pain. The deal is valued at an upfront cash payment of approximately $533 million for the remaining equity not owned by Boston Scientific, bringing the company’s total ownership to 100%.
The Nalu system, which received U.S. FDA 510(k) clearance in 2019, delivers targeted relief through a miniaturized, battery‑free implantable pulse generator powered wirelessly by an external disc and controlled via a smartphone app. Clinical trials (COMFORT and COMFORT 2) and real‑world data have shown significant pain reduction, with 87 % of participants reporting >50 % relief at 12 months and 94 % achieving clinically meaningful improvement across a broad range of chronic peripheral nerve pain conditions. The acquisition expands Boston Scientific’s neuromodulation offerings beyond spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation.
Boston Scientific expects the Nalu platform to generate sales in excess of $60 million in 2025 and to deliver year‑over‑year growth of more than 25 % in 2026. On an adjusted basis, the transaction is projected to be immaterial to adjusted earnings per share in 2026, slightly accretive in 2027, and increasingly accretive thereafter. The deal is expected to be more dilutive on a GAAP basis due to amortization and acquisition‑related charges, but the strategic fit and growth potential position the acquisition as a meaningful addition to Boston Scientific’s portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.